Skip to main content

Table 4 Therapy of the 89 malaria patients during January 2013–June 2017

From: High prevalence of malaria in a non-endemic setting: comparison of diagnostic tools and patient outcome during a four-year survey (2013–2017)

Parasitaemia range

Malaria species

Therapy

Follow-up

(parasitaemia reduction up to 0.001%)

24 h

48 h

72 h

> 72 h

< 0.001–< 1%

40 Pf

12 Quininea

1

1

1

8 Atovaquone + proguanil

1

14 Mefloquine

5

3

1

6 Piperaquine tetraphosphate + dihydroartemisinin

 

1

 

2 Pv

1 Chlorochine + primaquine

1 Chlorochine + ceftriaxone

 

9 Po

3 Mefloquine

2

1 Quinine

1 Chlorochine + primaquine

1 Quinine + doxycycline + primaquine

1d

1 Piperaquine tetraphosphate + dihydroartemisinin

2 unknown

 

1 Pm

1 Atovaquone + proguanil

1

 

1 Pf + Po

1 Atovaquone + proguanil + primaquine

 

1 Pf + Pm

1 Piperaquine tetraphosphate + dihydroartemisinin

1–10%

32 Pf

15 Quinineb

3

3

4

 

9 Mefloquine

1

2

4 Atovaquone + proguanil

1

2

4 Piperaquine tetraphosphate + dihydroartemisinin

2

> 10% negative

1 Pf

1 Quinine

1

2 Pf

2 Untreatedc

  1. –: no cases
  2. a6 out of 12 were in association with doxycycline; b 5 out of 15 were in association with clindamycine, doxycycline, ampicillin + sulbactam or ceftriaxone; c in these cases, according to the Italian Ministry of Health guidelines, no therapy was administered because microscopy was negative; d a full negativization was obtained in this case